Brief: Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
Acurx Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Acurx Pharmaceuticals Reports Q3 2024 Results And Provides Business Update
Acurx Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Acurx Announces Additional Ibezapolstat Ph2b Results In Cdi As Well As Anthrax Susceptibility To Acx-375 Analogues
Brief: Acurx Announces Results Of Its Pioneering Research With Ibezapolstat
Acurx Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: USPTO Grants Acurx Pharmaceuticals New Patent For Ibezapolstat To Treat CDI
Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals Files For Common Stock Offering Size Not Disclosed - SEC Filing
Acurx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Acurx Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Acurx Says European Medicines Agency Granted SME Designation For Ibezapolstat EU Development
Advisory: Alert from FMW Media Work wrongly tagged to multiple companies withdrawn
Brief: Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial In CDI Patients
Brief: Acurx Announces Positive Comparative Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Clinical Trial In CDI Patients
Brief: Acurx Announces Positive Phase 2B Results Showing 100% Of Patients Who Had Clinical Cure With Ibezapolstat Also Had Sustained Clinical Cure
Brief: Acurx Pharmaceuticals Says May Offer & Sell, From Time To Time, Shares Of Common Stock, Par Value $0.001 Per Share Of Up To $17 Mln